Issuer: | Globalstar, Inc. (the “Company” or “we”) |
Symbol: | GSAT (NYSE American) |
Size: | $59,999,999.85 |
Total Shares Offered: | 171,428,571 shares |
Option to Buy Additional Shares: | 25,714,285 shares |
Public Offering Price: | $0.35 per share |
Gross Spread: | $0.00525 per share |
Net Price: | $0.34475 per share |
Net Proceeds (after underwriting discounts and commissions and estimated expenses): | Approximately $58,900,000 or approximately $67,800,000 if the underwriter exercises its option to buy additional shares in full. |
Participation by Certain Existing Shareholders: | Our controlling shareholder, Thermo Funding II, LLC and its affiliates (collectively "Thermo"), and Mudrick Capital Management, L.P. ("Mudrick Capital") and Warlander Asset Management ("Warlander") have agreed to purchase 140,970,321, 14,849,954 and 7,471,153, respectively, shares of our common stock at the public offering price for total settlement amounts of $49.3 million, $5.2 million and $2.6 million, respectively, which include shares representing their respective pro rata ownership and backstop commitment. Thermo is controlled by James Monroe III, our Executive Chairman. Following such an investment, Thermo, Mudrick Capital and Warlander will beneficially own approximately 56.5%, 6.0% and 3.0%, respectively, if the underwriter does not exercise its option to purchase additional shares, compared to 53.0%, 5.6% and 2.8%, respectively, before the offering. |
Use of Proceeds: | As required under our Facility Agreement, 80% of the net proceeds from this offering will be deposited into a restricted account that may only be used to pay debt service obligations. We intend to use this amount, together with cash on hand, to fund a principal and interest payment of approximately $53 million due in December 2018 under our Facility Agreement. Depending on whether and when the underwriter exercises its option to purchase additional shares, the portion of the offering proceeds deposited in the restricted account may not be sufficient to pay the full amount of principal and interest due, in which case we will use cash on hand to pay the balance. The remainder of the proceeds from this offering will be used for general corporate purposes. We also expect the proceeds to qualify as an Equity Cure Contribution, allowing us to maintain compliance with the covenants under our Facility Agreement as of December 31, 2018. |
Trade Date: | Wednesday, December 19, 2018 |
Expected Closing Date: | Friday, December 21, 2018 |
Underwriter: | Cantor Fitzgerald & Co. |